Exactly what I was inferring. Did you ever read this from the company's website?
In two facilities with combined manufacturing, packaging and laboratory capacity exceeding 170,000 sq. ft., ANI develops and manufactures liquid, powder and oral solid dose products, including those requiring containment
Help me out. Is it even possible to make the millions of projected revenue in the amount of space?
Yo back Ratsky, Look the Biotechs took a huge hit today but they were one of the sectors that has risen the most. As far as DNDN, that's not me. I posted a legitimate evaluation about ANIP. It is NOT my opinion but Vestor Vest . and Ratsky, I don't give a fig what you think. Are you in 3rd or 4th grade?
Yo GRASSCROPPER...you've been tooting your horn a lot on "perceived" bio plays that have fallen flat--just review your posts. Why don't u just close down that flapper of yours and stop jinxing the sector and pronouncing the next REGN. Just shut up and stop saying all that glitters is gold. Weren't you a DNDN guy? NUF SAID.
ANI Pharm (ANIP
0.57 (0.86%) Monday, March 23, 2015
ANIP is undervalued compared to its Price of $66.55 per share, has below average safety, and is currently rated a Buy.
ANI Pharm (ANIP) Company Information
Business: ANI Pharmaceuticals, Inc., incorporated on April 11, 2001, is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. In two facilities with combined manufacturing, packaging and laboratory capacity totaling 173, 00 square feet, the Company manufactures oral solid dose products, as well as liquids and topicals, including narcotics.
Value: Value is a measure of a stock's current worth. ANIP has a current Value of $95.42 per share. Therefore, it is undervalued compared to its Price of $66.55 per share. Value is computed from forecasted earnings per share, forecasted earnings growth, profitability, interest, and inflation rates. Value increases when earnings, earnings growth rate and profitability increase, and when interest and inflation rates decrease. VectorVest advocates the purchase of undervalued stocks. At some point in time, a stock's Price and Value always will converge.
RV (Relative Value): RV is an indicator of long-term price appreciation potential. ANIP has an RV of 1.54, which is excellent on a scale of 0.00 to 2.00. This indicator is far superior to a simple comparison of Price and Value because it is computed from an analysis of projected price appreciation three years out, AAA Corporate Bond Rates, and risk. RV solves the riddle of whether it is preferable to buy High growth, High P/E stocks, or Low growth, Low P/E stocks. VectorVest favors the purchase of stocks with RV ratings above 1.00
Delljohn70, please provde your source stating that ANI sells in Europe.
According to the Roth presentation, Ani's CFO, Charlotte Arnold, clearly states at approx. the 23:20 minutes into the presentation that ANI generates all their revenue and profits in the United States.
You can go the News Page of ANI Pharmaceuticals website to find the link t to the presentation,
a lot of times these things rise after big insider sells. Its how the professional companies work.
skid marks all over the dollar too
One must not be a long or short all the time. If a stock is worth selling, then sell and equal amount short. When it is time to cover, buy a double amount, one to cover and one to hold. Better yet try margins. You will have plenty of chances to start all over again.
Reverse splits are bad. Splits to keep the pps between 20 and 30 are good. Spilts
do not have any effect on company performance but do affect investor perception, especially those small investors wishing to avoid odd lot fees (you are right - traders).